clinical trial · NCT07455058
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
Francis Medical Inc.·—·recruiting·n = 2,500
Prostate CancerVanquish Therapy
brief summary
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).
started
Jun 5, 2026
primary completion
Apr 30, 2041
completion
Jul 31, 2041
last updated
Jun 12, 2026
official title
Vanquish® Water Vapor Ablation for PrOstate CanceR: Long-Term Registry
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol